Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real‐world cohort study

Many patients with chronic hepatitis C virus (HCV) are on prolonged proton‐pump inhibitor (PPI) therapy and wish to remain on PPI therapy once treatment for HCV starts. A preliminary report recently suggested decrease rates of sustained virological response (SVR) for patients taking concomitant PPI...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Hepatology (Baltimore, Md.) Md.), 2016-12, Vol.64 (6), p.1893-1899
Hauptverfasser:	Tapper, Elliot B., Bacon, Bruce R., Curry, Michael P., Dieterich, Douglas T., Flamm, Steven L., Guest, Lauren E., Kowdley, Kris V., Lee, Yoori, Tsai, Naoky C., Younossi, Zobair M., Afdhal, Nezam H.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antiviral Agents - pharmacology Antiviral Agents - therapeutic use Benzimidazoles - pharmacology Benzimidazoles - therapeutic use Cohort Studies Drug Interactions Female Fluorenes - pharmacology Fluorenes - therapeutic use Hepacivirus - drug effects Hepatitis C virus Hepatitis C, Chronic - drug therapy Humans Male Middle Aged Proton Pump Inhibitors - pharmacology Proton Pump Inhibitors - therapeutic use Retrospective Studies Ribavirin - pharmacology Ribavirin - therapeutic use Sofosbuvir - pharmacology Sofosbuvir - therapeutic use Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!